The evolution of drug-resistant microorganisms in patients with prolonged mechanical ventilation

Am J Infect Control. 2009 Apr;37(3):231-6. doi: 10.1016/j.ajic.2008.05.016. Epub 2008 Nov 4.

Abstract

Background: Patients requiring prolonged mechanical ventilation (PMV) tend to become reservoirs of antimicrobial resistance. We assessed antimicrobial-resistant microorganisms in the respiratory tracts of patients receiving PMV.

Methods: Over a 6-month period, the microorganisms from tracheal aspirates of PMV patients with lower airway infection were analyzed.

Results: Antimicrobial use was greatest during the acute critical stage of respiratory failure. Antimicrobial resistance in Pseudomonas aeruginosa and Klebsiella pneumoniae peaked during the fourth to 15th weeks of PMV. Methicillin-resistant Staphylococcus aureus (MRSA) developed rapidly during the first 3 weeks of PMV. The acquisition of multidrug-resistant P aeruginosa and MRSA were significantly correlated with previous exposure to ceftazidime (odds ratio [OR] = 121.3 and 72.5; P = .01 and .01, respectively). The rise of multidrug-resistant Acinetobacter baumannii was significantly correlated with previous exposure to piperacillin/tazobactam (OR = 26.81; P = .02) and imipenem (OR = 16.91; P = .03). Using univariate and multivariate logistic regression models, the lower respiratory tract infections with multidrug-resistant microorganisms were independently associated with increased 6-month mortality (OR = 3.41; P < .01).

Conclusion: In patients receiving PMV, lower respiratory tract infection with multidrug-resistant microorganisms is common and is associated with higher mortality.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Anti-Bacterial Agents / pharmacology*
  • Anti-Bacterial Agents / therapeutic use
  • Bacteria / drug effects*
  • Bacteria / isolation & purification
  • Drug Resistance, Bacterial*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Pneumonia, Ventilator-Associated / drug therapy
  • Pneumonia, Ventilator-Associated / epidemiology
  • Pneumonia, Ventilator-Associated / microbiology*
  • Pneumonia, Ventilator-Associated / mortality
  • Respiration, Artificial / adverse effects*
  • Respiratory System / microbiology*

Substances

  • Anti-Bacterial Agents